Desogestrel ethinyl estradiol (DES) is a revolutionary hormonal contraceptive that has been used since the 1960s. It is a combination of two hormones, desogestrel and ethinyl estradiol, which work together to prevent pregnancy. DES is one of the most effective forms of contraception and is used by millions of women around the world. In this article, we will take a comprehensive look at the benefits of DES and how it can help women prevent pregnancy.
DES is a combination of two hormones, desogestrel and ethinyl estradiol, which work together to prevent pregnancy. When taken orally, DES works by preventing ovulation, which means that a woman's body does not release an egg that could potentially be fertilized by sperm. This process is known as ovulation inhibition. In addition, DES thickens the mucus in the cervix, which makes it harder for sperm to reach the uterus and fertilize an egg.
There are a number of benefits to using DES as a method of contraception. First, it is highly effective in preventing pregnancy. Studies have shown that DES is more than 99% effective when taken correctly and consistently. This makes it one of the most reliable forms of contraception available. In addition, DES is convenient and easy to use. It is available in pill form, which means that it can be taken at the same time each day. This makes it easy to remember and reduces the risk of forgetting to take the pill. Finally, DES is a safe and reliable form of contraception. It is a low-dose hormonal contraceptive, which means that it does not have the same side effects as other forms of contraception. Studies have shown that DES is safe to use for long periods of time and does not increase the risk of developing certain health conditions.
While DES is a safe and reliable form of contraception, there are some risks associated with its use. The most common side effects of DES are nausea, breast tenderness, headaches, and irregular bleeding. These side effects are usually mild and do not last long. In addition, DES can increase the risk of developing certain health conditions, such as blood clots, stroke, and heart attack. Women who are at an increased risk of developing these conditions should speak to their doctor before taking DES.
Desogestrel ethinyl estradiol (DES) is a revolutionary hormonal contraceptive that has been used since the 1960s. It is a combination of two hormones, desogestrel and ethinyl estradiol, which work together to prevent pregnancy. DES is one of the most effective forms of contraception and is used by millions of women around the world. It is highly effective in preventing pregnancy, is convenient and easy to use, and is a safe and reliable form of contraception. However, there are some risks associated with its use, such as nausea, breast tenderness, headaches, and irregular bleeding. Women who are at an increased risk of developing certain health conditions should speak to their doctor before taking DES.
1.
Breast Cancer Patients Living Longer Post-Medicaid Expansion
2.
Error on the MGUS-Autoimmune Disease Association.
3.
Patients with chronic myeloid leukemia who take nilotinib are at higher risk for diabetes and hyperlipidemia.
4.
The majority of cancer medications that receive expedited approval end up failing confirmatory trials.
5.
Unified Neuro/Psych Residency Program: New Proposal.
1.
Optimizing Melanoma Treatment: Strategies in Diagnosis, Clinical Research, and Physician Training
2.
Hemoglobin C: Understanding its Role in Sickle Cell Disease
3.
Beyond the Human Eye: How AI Is Redefining Brain Cancer Diagnosis Through Advanced Imaging
4.
Understanding Abemaciclib: A Breakthrough Treatment for Breast Cancer
5.
The Growing Challenge of Haematological Malignancies in Older Adults
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II
2.
Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial
3.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII
4.
A Conclusive Discussion on CROWN Trial and the Dawn of a New Era in Frontline Management of ALK+ NSCLC
5.
Efficient Management of First line ALK-rearranged NSCLC - Part VI
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation